| ［1］ |
Berishaj M，Gao SP，Ahmed S，et al.Stat3 is tyrosine-phosphorylated through the interleukin-6／glycoprotein 130／Janus kinase pathway in breast cancer.Breast Cancer Res，2007，9：R32.
|
| ［2］ |
Guo W，Pylayeva Y，Pepe A，et al.Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis.Cell，2006，126：489-502.
|
| ［3］ |
Proietti C，Salatino M，Rosemblit C，et al.Progestins induce transcriptional activation of signal transducer and activator of transcription 3（Stat3）via a Jak-and Src-dependent mechanism in breast cancer cells.Mol Cell Biol，2005，25：4826-4840.
|
| ［4］ |
Cheng G Z，Zhang W，Sun M，et al.Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function.JBiol Chem，2008，283：14665-14673.
|
| ［5］ |
Ishii Y，Waxman S，Germain D.Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3.Cancer Res，2008，68：852-860.
|
| ［6］ |
Tan K B，Yong W P，Putti T C.Cyclooxygenase-2 expression：a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast.Histopathology，2004，44：24-28.
|
| ［7］ |
Boland G P，Butt I S，Prasad R，et al.COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.Br JCancer，2004，90：423-429.
|
| ［8］ |
Visscher D W，Pankratz V S，Santisteban M，et al.Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer.JNatl Cancer Inst，2008，100：421-427.
|
| ［9］ |
Nassar A，Radhakrishnan A，Cabrero I A，et al.COX-2 expression in invasive breast cancer：correlation with prognostic parameters and outcome.Appl Immunohistochem Mol Morphol，2007，15：255-259.
|
| ［10］ |
Oliveira V M，Piato S，Silva M A.Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma，ductal carcinoma in situ，and adjacent normal epithelium.Breast Cancer Res Treat，2006，95：235-241.
|
| ［11］ |
张江宇，王颀，朱彩霞，等.血管内皮标记物在乳腺癌演变中的表达及意义.中华乳腺病杂志：电子版，2007，1：25-27.
|
| ［12］ |
Bumworth B，Popp S，Stark H J，et al.Gain of 11q／cyclin D1 overexpression is an essential early step in skin cancer development and causes abnormal tissue organization and differentiation.，2006，25：4399-4412.
|
| ［13］ |
Weroha S J，Li SA，Tawfik O，et al.Overexpression of cyclins D1 and D3 during estrogen-induced breast oncogenesis in female ACI rats.Carcinogenesis，2006，27：491-498.
|
| ［14］ |
Gao P，Wu Y G，et al.Alteration of cyclin D1 in Chinese patients with breast carcinoma and its correlation with Ki-67，pRb，and p53.Arch Med Res，2007，38：846-852.
|
| ［15］ |
Ahnström M，Nordenskjöld B，Rutqvist LE，et al.Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance.Breast Cancer Res Treat，2005，91：145-151.
|
| ［16］ |
Ishii Y，Pirkmaier A，Alvarez JV，et al.Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.J Natl Cancer Inst，2006，98：1238-1247.
|
| ［17］ |
Huang JW，Shiau CW，Yang Y T，et al.Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells.Mol Pharmacol，2005，67：1342-1348.
|
| ［18］ |
Sebastian S，Settleman J，Reshkin S，et al.The Comp lexity of Targeting EGFR Signalling in Cancer：from Exp ression to Turnover.Biochim Biophys Acta，2006，1766：120-139.
|
| ［19］ |
Taron M，Ichinose Y，Rosell R，et al.Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.Clin Cancer Res，2005，11：5878-2885.
|
| ［20］ |
Riely G J，Pao W，Pham D，et al.Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.Clin Cancer Res，2006，12：839-844.
|
| ［21］ |
Huang S，Armstrong E A，Benavente S，et al.Dual-agent molecular targeting of the epidermal growth factor receptor（EGFR）：combining anti-EGFR antibody with tyrosine kinase inhibitor.Cancer Res，2004，64：5355-5362.
|
| ［22］ |
Dai Q，Ling Y H，Lia M，et al.Enhanced sensitivity to the HER1／epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.Clin Cancer Res，2005，11：1572-1578.
|
| ［23］ |
Massarweh S，Osbome C K，Jiang S，et al.Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive，HER-2／neu-positive breast cancer.Cancer Res，2006，66：8266-8273.
|
| ［24］ |
Massarweh S，Osbome CK，Creighton C J，et al.Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.Cancer Res，2008，68：826-833.
|
| ［25］ |
Ji H，Liu Y E，Jia T，et al.Identification of a breast cancer-specific gene，BCSG1，by direct differential cDNA sequencing.Cancer Res，1997，57：759-764.
|
| ［26］ |
Lavedan C，Leroy E，Dehejia A，et al.Identification，localization and characterization of the human gamma-synuclein gene.Hum Genet，1998，103：106-112.
|
| ［27］ |
Lu A，Li Q，Liu J.Regulatory mechanisms for abnormal expression of the human breast cancer specific gene 1 in breast cancer cells.Sci China C Life Sci，2006，49：403-408.
|
| ［28］ |
Singh V K，Zhou Y，Marsh J A，et al.Synuclein-gamma targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs.Cancer Res，2007，67：626-633.
|
| ［29］ |
Guo J，Shou C，Meng L，et al.Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer.Int J Cancer，2007，121：1296-1305.
|
| ［30］ |
Wu K，Quan Z，Weng Z，et al.Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis.Breast Cancer Res Treat，2007，101：259-267.
|
| ［31］ |
Singh V K，Jia Z.Targeting synuclein-gamma to counteract drug resistance in cancer.Expert Opin Ther Targets，2008，12：59-68.
|